Prostate Cancer Pipeline Review, H1 2013


#164916

414pages

Global Markets Direct

$ 2500

In Stock


Global Markets Directs, 'Prostate Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. 

Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Prostate Cancer.
  • A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Prostate Cancer Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Prostate Cancer 17
Prostate Cancer Therapeutics under Development by Companies 19
Prostate Cancer Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Prostate Cancer Therapeutics Products under Development by Companies 43
Prostate Cancer Therapeutics Products under Investigation by Universities/Institutes 64
Companies Involved in Prostate Cancer Therapeutics Development 68
Bristol-Myers Squibb Company 68
Johnson & Johnson 69
Boehringer Ingelheim GmbH 70
Celsion Corporation 71
Amgen Inc. 72
Sanofi-Aventis 73
Adherex Technologies Inc. 74
AstraZeneca PLC 75
Eli Lilly and Company 76
Viralytics Ltd. 77
GlaxoSmithKline plc 78
Bioniche Life Sciences, Inc. 79
Genentech, Inc. 80
Inovio Biomedical Corporation 81
Bavarian Nordic A/S 82
Isis Pharmaceuticals, Inc. 83
Biotest AG 84
GenVec, Inc. 85
Merck & Co., Inc. 86
AbGenomics International, Inc. 87
Emergent BioSolutions Inc. 88
Oxford BioMedica plc 89
Otsuka Pharmaceutical Co., Ltd. 90
Generex Biotechnology Corporation 91
Takeda Pharmaceutical Company Limited 92
Plexxikon Inc. 93
Amorfix Life Sciences Ltd. 94
Ipsen S.A. 95
Bio-Path Holdings, Inc. 96
ZIOPHARM Oncology, Inc. 97
Millennium Pharmaceuticals, Inc. 98
Novartis AG 99
Aphios Corporation 100
Astellas Pharma Inc. 101
BioMarin Pharmaceutical Inc. 102
GTx, Inc. 103
Nippon Shinyaku Co., Ltd. 104
Orion Corporation 105
Pfizer Inc. 106
SuperGen, Inc. 107
Teva Pharmaceutical Industries Limited 108
Progenics Pharmaceuticals, Inc. 109
Sun Pharmaceutical Industries Limited 110
Santaris Pharma A/S 111
Exelixis, Inc. 112
Aduro BioTech 113
Alfacell Corporation 114
Bayer AG 115
MannKind Corporation 116
Halozyme Therapeutics 117
Merck KGaA 118
Advaxis, Inc. 119
Genesis Research and Development Corporation Ltd. 120
Hollis-Eden Pharmaceuticals, Inc. 121
Celldex Therapeutics, Inc. 122
Anavex Life Sciences Corp. 123
ValiRx Plc 124
Active Biotech AB 125
AEterna Zentaris Inc. 126
IMMUNOMEDICS, INC 127
Antisense Therapeutics Limited 128
Marshall Edwards, Inc. 129
Bionomics Limited 130
Molecular Insight Pharmaceuticals, Inc. 131
Northwest Biotherapeutics, Inc. 132
Nymox Pharmaceutical Corporation 133
Cleveland BioLabs, Inc. 134
Oncolytics Biotech Inc. 135
Oncothyreon Inc 136
Compugen Ltd. 137
Osta Biotechnologies Inc. 138
Patrys Limited 139
Peregrine Pharmaceuticals, Inc. 140
Medivation, Inc. 141
La Jolla Pharmaceutical Company 142
Telik, Inc. 143
Institute of Cancer Research 144
Soligenix, Inc. 145
Regeneron Pharmaceuticals, Inc. 146
Champions Biotechnology, Inc. 147
Oncogenex Pharmaceuticals, Inc. 148
ProMetic Life Sciences Inc. 149
Progen Pharmaceuticals Limited 150
Green Cross Corporation 151
Innocell Corporation 152
Threshold Pharmaceuticals, Inc. 153
Synta Pharmaceuticals Corp. 154
Sareum Holdings plc 155
Oasmia Pharmaceutical AB 156
Protox Therapeutics Inc. 157
e-Therapeutics plc 158
RXi Pharmaceuticals Corporation 159
Hybrigenics S.A. 160
Rexahn Pharmaceuticals, Inc. 161
Merrion Pharmaceuticals Plc 162
Nanobiotix 163
Oryzon 164
Affitech A/S 165
Debiopharm Group 166
Colby Pharmaceutical Company 167
Supratek Pharma Inc. 168
Camurus AB 169
Fusion Antibodies Ltd 170
Actinium Pharmaceuticals, Inc. 171
Phosphagenics Limited 172
Actis Biologics, Inc 173
Nerviano Medical Sciences S.r.l. 174
Med Discovery SA 175
Pro-Cure Therapeutics Limited 176
Vaxon Biotech 177
Advantagene, Inc. 178
CureVac GmbH 179
Alethia Biotherapeutics Inc. 180
GenSpera, Inc. 181
NormOxys, Inc. 182
Ascenta Therapeutics, Inc. 183
Tokai Pharmaceuticals, Inc. 184
Coronado Biosciences, Inc. 185
MacroGenics, Inc. 186
Pervasis Therapeutics, Inc. 187
Antyra, Inc. 188
Pantarhei Bioscience BV 189
Azaya Therapeutics, Inc. 190
GP Pharm, S.A. 191
IC-MedTech, Inc. 192
Innate Therapeutics Limited 193
Iconic Therapeutics, Inc. 194
ProNAi Therapeutics, Inc. 195
Angion Biomedica Corp. 196
Jennerex Biotherapeutics, Inc. 197
Axelar AB 198
Endocyte, Inc. 199
Omnitura Therapeutics Inc. 200
AndroScience Corporation 201
Pharminox Limited 202
Thrasos, Inc. 203
KangLaiTe USA 204
NovaLead Pharma Pvt. Ltd. 205
Esperance Pharmaceuticals, Inc. 206
Mirna Therapeutics, Inc. 207
Omeros Corporation 208
Transtech Pharma, Inc. 209
PharmaNova Inc. 210
ImmunoVaccine Technologies Inc. 211
Peptron, Inc. 212
Globeimmune, Inc. 213
GENova Biotherapeutics, Inc. 214
NewLink Genetics Corporation 215
PepTcell Limited 216
Cellceutix Corporation 217
PharmaMar, S.A. 218
TVAX Biomedical, LLC 219
Genetic Immunity, LLC 220
Quintessence Biosciences, Inc. 221
Bellicum Pharmaceuticals, Inc. 222
Virax Holdings Limited 223
Aprea AB. 224
Kinex Pharmaceuticals, LLC 225
Adamis Pharmaceuticals Corporation 226
Tigris Pharmaceuticals, Inc. 227
Cylene Pharmaceuticals, Inc. 228
Genelux Corporation 229
Lipopharma 230
Viventia Biotechnologies Inc. 231
IRX Therapeutics, Inc. 232
Medestea Research & Production S.p.A. 233
Ferring Pharmaceuticals, Inc. 234
Advanced Cancer Therapeutics 235
Elara Pharmaceuticals GmbH 236
Cancer Therapeutics CRC Pty Ltd 237
Targa Therapeutics Corp. 238
BioProspecting NB, Inc. 239
Celtic Therapeutics Holdings L.P. 240
Aragon Pharmaceuticals, Inc. 241
BHR Pharma, LLC. 242
iCeutica, Inc. 243
Ausio Pharmaceuticals, LLC 244
Steba Laboratories Ltd. 245
Errant Gene Therapeutics, LLC 246
Mebiopharm Co., Ltd. 247
Polaris Group 248
EyeGene, Inc. 249
DEKK-TEC, Inc. 250
Serometrix, LLC 251
ImQuest Life Sciences 252
CytoVac A/S 253
Prostate Cancer Therapeutics Assessment 254
Assessment by Monotherapy Products 254
Assessment by Combination Products 255
Assessment by Route of Administration 256
Assessment by Molecule Type 259
Drug Profiles 262
denosumab - Drug Profile 262
denosumab - Drug Profile 265
ipilimumab - Drug Profile 268
degarelix 3 Month Formulation - Drug Profile 271
leuprolide acetate second generation - Drug Profile 295
custirsen sodium + [docetaxel] - Drug Profile 297
Dastinib + Docetaxel + Prednisone - Drug Profile 299
custirsen sodium + [docetaxel] + [prednisone] - Drug Profile 300
aflibercept + [docetaxel] + [prednisone] - Drug Profile 302
cabazitaxel - Drug Profile 304
orteronel + [prednisone] - Drug Profile 305
aflibercept - Drug Profile 306
ProstAtak - Drug Profile 310
Debio-8206 SC - Drug Profile 312
leuprolide acetate - Drug Profile 313
leuprolide acetate Depot 3 Months - Drug Profile 314
Prostate Cancer Therapeutics Drug Profile Updates 315
Prostate Cancer Therapeutics Discontinued Products 372
Prostate Cancer Therapeutics - Dormant Products 378
Prostate Cancer Product Development Milestones 404
Featured News & Press Releases 404

Appendix 411
Methodology 411
Coverage 411
Secondary Research 411
Primary Research 411
Expert Panel Validation 411
Contact Us 412
Disclaimer 412

Number of Products Under Development for Prostate Cancer, H1 2013 19
Products under Development for Prostate Cancer Comparative Analysis, H1 2013 20
Number of Products under Development by Companies, H1 2013 22
Number of Products under Development by Companies, H1 2013 (Contd..1) 23
Number of Products under Development by Companies, H1 2013 (Contd..2) 24
Number of Products under Development by Companies, H1 2013 (Contd..3) 25
Number of Products under Development by Companies, H1 2013 (Contd..4) 26
Number of Products under Development by Companies, H1 2013 (Contd..5) 27
Number of Products under Development by Companies, H1 2013 (Contd..6) 28
Number of Products under Development by Companies, H1 2013 (Contd..7) 29
Number of Products under Development by Companies, H1 2013 (Contd..8) 30
Number of Products under Development by Companies, H1 2013 (Contd..9) 31
Number of Products under Development by Companies, H1 2013 (Contd..10) 32
Number of Products under Development by Companies, H1 2013 (Contd..11) 33
Number of Products under Development by Companies, H1 2013 (Contd..12) 34
Number of Products under Development by Companies, H1 2013 (Contd..13) 35
Number of Products under Development by Companies, H1 2013 (Contd..14) 36
Number of Products under Investigation by Universities/Institutes, H1 2013 38
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 39
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 40
Comparative Analysis by Late Stage Development, H1 2013 41
Comparative Analysis by Mid Clinical Stage Development, H1 2013 42
Comparative Analysis by Early Clinical Stage Development, H1 2013 43
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 44
Products under Development by Companies, H1 2013 45
Products under Development by Companies, H1 2013 (Contd..1) 46
Products under Development by Companies, H1 2013 (Contd..2) 47
Products under Development by Companies, H1 2013 (Contd..3) 48
Products under Development by Companies, H1 2013 (Contd..4) 49
Products under Development by Companies, H1 2013 (Contd..5) 50
Products under Development by Companies, H1 2013 (Contd..6) 51
Products under Development by Companies, H1 2013 (Contd..7) 52
Products under Development by Companies, H1 2013 (Contd..8) 53
Products under Development by Companies, H1 2013 (Contd..9) 54
Products under Development by Companies, H1 2013 (Contd..10) 55
Products under Development by Companies, H1 2013 (Contd..11) 56
Products under Development by Companies, H1 2013 (Contd..12) 57
Products under Development by Companies, H1 2013 (Contd..13) 58
Products under Development by Companies, H1 2013 (Contd..14) 59
Products under Development by Companies, H1 2013 (Contd..15) 60
Products under Development by Companies, H1 2013 (Contd..16) 61
Products under Development by Companies, H1 2013 (Contd..17) 62
Products under Development by Companies, H1 2013 (Contd..18) 63
Products under Development by Companies, H1 2013 (Contd..19) 64
Products under Development by Companies, H1 2013 (Contd..20) 65
Products under Investigation by Universities/Institutes, H1 2013 66
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 67
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 68
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 69
Bristol-Myers Squibb Company, H1 2013 70
Johnson & Johnson, H1 2013 71
Boehringer Ingelheim GmbH, H1 2013 72
Celsion Corporation, H1 2013 73
Amgen Inc., H1 2013 74
Sanofi-Aventis, H1 2013 75
Adherex Technologies Inc., H1 2013 76
AstraZeneca PLC, H1 2013 77
Eli Lilly and Company, H1 2013 78
Viralytics Ltd., H1 2013 79
GlaxoSmithKline plc, H1 2013 80
Bioniche Life Sciences, Inc., H1 2013 81
Genentech, Inc., H1 2013 82
Inovio Biomedical Corporation, H1 2013 83
Bavarian Nordic A/S, H1 2013 84
Isis Pharmaceuticals, Inc., H1 2013 85
Biotest AG, H1 2013 86
GenVec, Inc., H1 2013 87
Merck & Co., Inc., H1 2013 88
AbGenomics International, Inc., H1 2013 89
Emergent BioSolutions Inc., H1 2013 90
Oxford BioMedica plc, H1 2013 91
Otsuka Pharmaceutical Co., Ltd., H1 2013 92
Generex Biotechnology Corporation, H1 2013 93
Takeda Pharmaceutical Company Limited, H1 2013 94
Plexxikon Inc., H1 2013 95
Amorfix Life Sciences Ltd., H1 2013 96
Ipsen S.A., H1 2013 97
Bio-Path Holdings, Inc., H1 2013 98
ZIOPHARM Oncology, Inc., H1 2013 99
Millennium Pharmaceuticals, Inc., H1 2013 100
Novartis AG, H1 2013 101
Aphios Corporation, H1 2013 102
Astellas Pharma Inc., H1 2013 103
BioMarin Pharmaceutical Inc., H1 2013 104
GTx, Inc., H1 2013 105
Nippon Shinyaku Co., Ltd., H1 2013 106
Orion Corporation, H1 2013 107
Pfizer Inc., H1 2013 108
SuperGen, Inc., H1 2013 109
Teva Pharmaceutical Industries Limited, H1 2013 110
Progenics Pharmaceuticals, Inc., H1 2013 111
Sun Pharmaceutical Industries Limited, H1 2013 112
Santaris Pharma A/S, H1 2013 113
Exelixis, Inc., H1 2013 114
Aduro BioTech, H1 2013 115
Alfacell Corporation, H1 2013 116
Bayer AG, H1 2013 117
MannKind Corporation, H1 2013 118
Halozyme Therapeutics, H1 2013 119
Merck KGaA, H1 2013 120
Advaxis, Inc., H1 2013 121
Genesis Research and Development Corporation Ltd., H1 2013 122
Hollis-Eden Pharmaceuticals, Inc., H1 2013 123
Celldex Therapeutics, Inc., H1 2013 124
Anavex Life Sciences Corp., H1 2013 125
ValiRx Plc, H1 2013 126
Active Biotech AB, H1 2013 127
AEterna Zentaris Inc., H1 2013 128
IMMUNOMEDICS, INC, H1 2013 129
Antisense Therapeutics Limited, H1 2013 130
Marshall Edwards, Inc., H1 2013 131
Bionomics Limited, H1 2013 132
Molecular Insight Pharmaceuticals, Inc., H1 2013 133
Northwest Biotherapeutics, Inc., H1 2013 134
Nymox Pharmaceutical Corporation, H1 2013 135
Cleveland BioLabs, Inc., H1 2013 136
Oncolytics Biotech Inc., H1 2013 137
Oncothyreon Inc, H1 2013 138
Compugen Ltd., H1 2013 139
Osta Biotechnologies Inc., H1 2013 140
Patrys Limited, H1 2013 141
Peregrine Pharmaceuticals, Inc., H1 2013 142
Medivation, Inc., H1 2013 143
La Jolla Pharmaceutical Company, H1 2013 144
Telik, Inc., H1 2013 145
Institute of Cancer Research, H1 2013 146
Soligenix, Inc., H1 2013 147
Regeneron Pharmaceuticals, Inc., H1 2013 148
Champions Biotechnology, Inc., H1 2013 149
Oncogenex Pharmaceuticals, Inc., H1 2013 150
ProMetic Life Sciences Inc., H1 2013 151
Progen Pharmaceuticals Limited, H1 2013 152
Green Cross Corporation, H1 2013 153
Innocell Corporation, H1 2013 154
Threshold Pharmaceuticals, Inc., H1 2013 155
Synta Pharmaceuticals Corp., H1 2013 156
Sareum Holdings plc, H1 2013 157
Oasmia Pharmaceutical AB, H1 2013 158
Protox Therapeutics Inc., H1 2013 159
e-Therapeutics plc, H1 2013 160
RXi Pharmaceuticals Corporation, H1 2013 161
Hybrigenics S.A., H1 2013 162
Rexahn Pharmaceuticals, Inc., H1 2013 163
Merrion Pharmaceuticals Plc, H1 2013 164
Nanobiotix, H1 2013 165
Oryzon, H1 2013 166
Affitech A/S, H1 2013 167
Debiopharm Group, H1 2013 168
Colby Pharmaceutical Company, H1 2013 169
Supratek Pharma Inc., H1 2013 170
Camurus AB, H1 2013 171
Fusion Antibodies Ltd, H1 2013 172
Actinium Pharmaceuticals, Inc., H1 2013 173
Phosphagenics Limited, H1 2013 174
Actis Biologics, Inc, H1 2013 175
Nerviano Medical Sciences S.r.l., H1 2013 176
Med Discovery SA, H1 2013 177
Pro-Cure Therapeutics Limited, H1 2013 178
Vaxon Biotech, H1 2013 179
Advantagene, Inc., H1 2013 180
CureVac GmbH, H1 2013 181
Alethia Biotherapeutics Inc., H1 2013 182
GenSpera, Inc., H1 2013 183
NormOxys, Inc., H1 2013 184
Ascenta Therapeutics, Inc., H1 2013 185
Tokai Pharmaceuticals, Inc., H1 2013 186
Coronado Biosciences, Inc., H1 2013 187
MacroGenics, Inc., H1 2013 188
Pervasis Therapeutics, Inc., H1 2013 189
Antyra, Inc., H1 2013 190
Pantarhei Bioscience BV, H1 2013 191
Azaya Therapeutics, Inc., H1 2013 192
GP Pharm, S.A., H1 2013 193
IC-MedTech, Inc., H1 2013 194
Innate Therapeutics Limited, H1 2013 195
Iconic Therapeutics, Inc., H1 2013 196
ProNAi Therapeutics, Inc., H1 2013 197
Angion Biomedica Corp., H1 2013 198
Jennerex Biotherapeutics, Inc., H1 2013 199
Axelar AB, H1 2013 200
Endocyte, Inc., H1 2013 201
Omnitura Therapeutics Inc., H1 2013 202
AndroScience Corporation, H1 2013 203
Pharminox Limited, H1 2013 204
Thrasos, Inc., H1 2013 205
KangLaiTe USA, H1 2013 206
NovaLead Pharma Pvt. Ltd., H1 2013 207
Esperance Pharmaceuticals, Inc., H1 2013 208
Mirna Therapeutics, Inc., H1 2013 209
Omeros Corporation, H1 2013 210
Transtech Pharma, Inc., H1 2013 211
PharmaNova Inc., H1 2013 212
ImmunoVaccine Technologies Inc., H1 2013 213
Peptron, Inc., H1 2013 214
Globeimmune, Inc., H1 2013 215
GENova Biotherapeutics, Inc., H1 2013 216
NewLink Genetics Corporation, H1 2013 217
PepTcell Limited, H1 2013 218
Cellceutix Corporation, H1 2013 219
PharmaMar, S.A., H1 2013 220
Number of Products under Development for Prostate Cancer, H1 2013 19
Products under Development for Prostate Cancer Comparative Analysis, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 37
Late Stage Products, H1 2013 41
Mid Clinical Stage Products, H1 2013 42
Early Clinical Stage Products, H1 2013 43
Discovery and Pre-Clinical Stage Products, H1 2013 44
Assessment by Monotherapy Products, H1 2013 256
Assessment by Combination Products, H1 2013 257
Assessment by Route of Administration, H1 2013 258
Assessment by Stage and Route of Administration, H1 2013 259
Assessment by Molecule Type, H1 2013 261
Assessment by Stage and Molecule Type, H1 2013 262